Bright Minds Biosciences (NASDAQ:DRUG) shares are under the spotlight following the announcement of "positive and significant" topline results from its Phase 2 BREAKTHROUGH study.
Alkermes (NASDAQ:ALKS) announced on January 6, 2026, that the U.S. FDA has granted Breakthrough Therapy Designation to alixorexton (formerly ALKS 2680) for the treatment of narcolepsy type 1 (NT1).
Apogee Therapeutics (NASDAQ:APGE) shares are trending today after the company reported positive interim Phase 1b results for zumilokibart (APG777), its half-life extended anti-IL-13 antibody.
Aclarion (NASDAQ:ACON) reached a significant clinical milestone on Tuesday, January 6, 2026, announcing the first patient enrollments at two prestigious new sites: Northwestern Medicine and Scripps Health.
This expansion brings the total number of active enrollment sites to four, with seven leading U.S. spine centers having completed full regulatory and operational setup.
AngioDynamics (NASDAQ:ANGO) on Tuesday reported fiscal second-quarter results that highlighted continued momentum in its high-margin Med Tech portfolio, with overall net sales rising 8.8% year over year to $79.4 million for the period ended Nov. 30, 2025.
Oculis Holding AG (NASDAQ:OCS) shares climbed today after the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Privosegtor (OCS-05), a first-in-class neuroprotective candidate for the treatment of optic neuritis.
The designation, announced January 6, 2026, marks a major milestone for the Swiss biotech as it targets a $7 billion U.S. market for optic neuropathies.
Natera (NASDAQ:NTRA) announced a significant clinical breakthrough today, revealing that its pivotal Phase III ALTAIR trial successfully reached statistical significance following a reclassification of patient data.
The Trump administration is rolling back federal child care funding rules as officials cite fraud concerns and freeze payments.
US regulators have cut the list of vaccines routinely recommended for all children, citing international comparisons and public trust concerns.
Moderna (NASDAQ:MRNA) officially moved to challenge the multi-billion-dollar seasonal influenza market today, submitting marketing authorization applications for its investigational vaccine, mRNA-1010, to regulators in the U.S., Europe, Canada, and Australia.
Zenas BioPharma (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company focused on developing transformative immunology-based therapies for autoimmune diseases, today announced positive topline results from the Phase 3 INDIGO registrational trial evaluating obexelimab in patients with Immunoglobulin G4-Related Disease (IgG4-RD).
Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric disorders and neurodegenerative diseases, today reported positive topline results from a Phase 1b signal-seeking study evaluating NMRA-511 as a potential treatment for agitation in patients with Alzheimer's disease.
-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)
